Systemic administration of heparin ameliorates radiation-induced oral mucositis—preclinical studies in mice

Springer Science and Business Media LLC - Tập 194 - Trang 686-692 - 2018
Maria Kowaliuk1, Eva Bozsaky1, Sylvia Gruber1, Peter Kuess2, Wolfgang Dörr1
1Department of Radiotherapy—ATRAB—Applied and Translational Radiobiology and Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria
2Department of Radiotherapy—Christian Doppler Laboratory for Medical Radiation Physics for Radiation Oncology, Medical University of Vienna, Vienna, Austria

Tóm tắt

The present study investigates the impact of systemic application of heparins on the manifestation of radiation-induced oral mucositis in a well-established mouse model. Male C3H/Neu mice were irradiated with either single-dose or fractionated irradiation protocols with 5 × 3 Gy/week, given over one (days 0–4) or two (days 0–4, 7–11) weeks. All fractionation protocols were concluded by a local test irradiation (day 7/14) using graded doses to generate complete dose–effect curves. Daily doses of unfractionated or low molecular weight heparin (40 or 200 I.U./mouse, respectively) were applied subcutaneously over varying time intervals. The incidence and the time course of mucosal ulceration, corresponding to confluent mucositis in patients (RTOG/EORTC grade 3), were analysed as clinically relevant endpoints. Systemic application of heparins significantly increased the iso-effective doses for the induction of mucosal ulceration, particularly in combination with fractionated irradiation protocols. Moreover, a tentative prolongation of the latent time and a pronounced reduction of the ulcer duration were observed. These data provide the first evidence for a protective and/or mitigative effect of heparins for radiation-induced oral mucositis. Further studies are ongoing investigating the underlying mechanism.

Tài liệu tham khảo

Sonis ST (2004) Pathobiology of mucositis. Semin Oncol Nurs 20:11–15 Viet CT, Corby PM, Akinwande A, Schmidt BL (2014) Review of preclinical studies on treatment of mucositis and associated pain. J Dent Res 93:868–875 Sonis ST (2012) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5:7–13 Oduah E, Linhardt R, Sharfstein S (2016) Heparin: past, present, and future. Pharmaceuticals (Basel) 9:38 Page C (2013) Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol 2013:13 Dörr W, Spekl K, Farrell CL (2002) Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 54:245–251 Dörr W, Herrmann T, Reitemeier B et al (2008) Folgen der Strahlentherapie in der Mundhöhle. Zahnmed Up2date 6:543–569 Dörr W, Spekl K, Martin M (2002) Radiation-induced oral mucositis in mice : strain differences. Cell Prolif 35:60–67 Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36:195–203 Dörr W, Herrmann T, Trott K (2017) Normal tissue tolerance. Transl Cancer Res 6:840–851 Thourani VH, Brar SS, Kennedy TP et al (2000) Non-anticoagulant heparin inhibits NF-κ B activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 48:2084–2093 Lee JH, Lee J, Seo GH (2007) Heparin inhibits NF- κ B activation and increases cell death in cerebral endothelial cells after oxygen-glucose deprivation. J Mol Neurosci 32:145–154 Spratte J, Meyer H, Endlich N et al (2013) Heparin inhibits TNF- a signaling in human endometrial stromal cells by interaction with NF- k B. Mol Hum Reprod 19:227–236 Al-Ansari S, Zecha JAEM, Barasch A et al (2015) Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2:202–211 Grzela T, Brawura-Biskupski-Samaha R, Jelenska MM, Szmidt J (2008) Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 35:159–161 D’Hondt L, Lonchay C, André M, Canon JL (2006) Oral mucositis induced by anticancer treatments: physiopathology and treatments. Ther Clin Risk Manag 2:159–168 Kim PJ, Sakaguchi K, Sakamoto H et al (1998) Colocalization of heparin and receptor binding sites on keratinocyte growth factor. Biochemistry 37:8853–8862 Jaal J, Richter C, Dörr W (2010) Effect of recombinant human keratinocyte growth factor ( Delta 23rHuKGF, Palifermin ) on inflammatory and immune changes in mouse tongue during fractionated irradiation. Int J Radiat Biol 86:860–866 Hallahan DE, Subbulakshmi V (1997) Intercellular adhesion molecule 1 knockout abrogates radiation. Proc Natl Acad Sci Usa 94:6432–6437 Quaranta M, Erez O, Mastrolia SA et al (2015) The physiologic and therapeutic role of heparin in implantation and placentation. PeerJ 3:e691 Dörr W (1997) Strahlenbiologische Parameter der radiogenen Mucositis enoralis. Habilitation manuscript